Bayhill Therapeutics and the Juvenile Diabetes Research Foundation Announce Research Collaboration
News Oct 31, 2008
Bayhill Therapeutics, Inc. and the Juvenile Diabetes Research Foundation has announced a partnership to support Bayhill’s ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes.
BHT-3021 is an antigen-specific immunotherapeutic DNA vaccine designed to reverse the underlying autoimmune disease process in diabetes, and slow down or halt further loss of pancreatic beta cell function.
"We are very pleased to have the support of JDRF as we advance the clinical development of BHT-3021," said Mark W. Schwartz, Ph.D., Bayhill’s President and CEO.
"This agreement demonstrates JDRF's commitment to funding ground-breaking clinical research and to the development of novel therapeutics that can potentially have an important impact on the lives of people with diabetes. There are currently no disease-modifying products available to the millions of patients suffering from this disease. We believe BHT-3021 will provide a better treatment alternative for them,” Schwartz said.
JDRF funds diabetes research across a range of scientific areas, including beta cell regeneration, immunology, islet cell replacement, complications, genetics, and technological innovations and therapeutics to improve metabolic control.
The agreement with Bayhill is a part of JDRF's innovative Industry Discovery and Development Partnership program, through which JDRF partners with pharmaceutical, biotech, and medical device businesses looking to develop drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1 diabetes and its complications.
Through its IDDP Program, JDRF will provide up to $3 million toward the Phase I/II clinical trial. Funding will be based on Bayhill attaining specific clinical milestones expected to be reached by the third quarter of 2009.
Through its IDDP program, JDRF has funded some 25 companies, representing approximately $29 million in diabetes science.